Clinaptis Research

Independent analysis argues headline efficacy overstates competitive advantage, while concluding the overall clinical profile remains fundamentally credible.

Report develops a reverse-solve valuation framework separating VK2735's subcutaneous valuation floor from the unresolved commercial opportunity of the oral obesity program.